The AVEN Knouckout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human liver adenocarcinoma cell line SK-HEP-1. This product provides a genetically heterogeneous pool of cells with disrupted AVEN gene expression, enabling functional studies of AVEN-dependent apoptosis regulation in a clinically relevant hepatic cancer model.
The SK-HEP-1 cell line originates from a liver adenocarcinoma of a 52-year-old male patient. As an epithelial cell line, SK-HEP-1 retains characteristics of hepatic tumor cells and is widely employed in liver cancer research, particularly for studying intrinsic apoptosis pathways and drug resistance mechanisms. Its robust growth and reproducible response to apoptotic stimuli make it a suitable host for CRISPR-mediated gene disruption.
AVEN functions as a critical apoptosis inhibitor by directly binding Apaf-1, thereby interfering with apoptosome assembly and subsequent recruitment and activation of caspase-9. This interaction suppresses the caspase cascade, including cleavage of caspase-3, and ultimately blocks cytochrome c-induced cell death. AVEN has also been reported to interact with anti-apoptotic members Bcl-2 and Bcl-xL, further reinforcing survival signaling. Upstream, AVEN expression is modulated by cellular stress and DNA damage response pathways, positioning it as a key node in the intrinsic mitochondrial apoptosis pathway. Downstream targets include pro-apoptotic factors Bak and Bax, although AVEN primarily exerts its protective effect at the level of caspase-9 inhibition.
In the SK-HEP-1 liver adenocarcinoma model, disruption of AVEN expression by CRISPR/Cas9 is expected to lower the apoptotic threshold, rendering cells more vulnerable to intrinsic death signals. This sensitization is particularly relevant for investigating mechanisms of therapy resistance in hepatocellular carcinoma, where upregulation of anti-apoptotic factors often limits the efficacy of chemotherapeutic agents. The polyclonal knockout population allows assessment of AVEN dependency across a range of genetic backgrounds, mimicking tumor heterogeneity.
This polyclonal AVEN knockout product is well-suited for applications in apoptosis research, including comparative analysis of apoptotic responses by Annexin V staining and flow cytometry, as well as caspase-3/9 activity measurements. Co-immunoprecipitation studies can be performed to validate disrupted AVEN?CApaf-1 binding, while Western blotting and qPCR enable confirmation of gene disruption and downstream effector changes. The cells provide a valuable platform for drug sensitivity assays to screen pro-apoptotic compounds that exploit AVEN deficiency, contributing to the development of therapies targeting therapy-resistant malignancies. For further information on using this knockout model in your research, please contact Ascent Research.
